A
fter its approval by the U.S. Food and Drug Administration (FDA) in 1994, metformin became the recommended initial treatment for type 2 diabetes mellitus in the United States (1). Beyond its glycemic benefits, metformin typically does not cause weight gain or hypoglycemia and may be associated with lower mortality (2, 3). Because of concerns regarding lactic acidosis with use of phenformin, a related biguanide withdrawn from the market in 1977, the FDA applied a boxed warning to metformin concurrent with its approval (4). This warning cautioned against using metformin in the setting of chronic kidney disease (CKD), which may impair excretion of the drug, and recommended caution in patients with conditions that may promote lactate accumulation (such as congestive heart failure [CHF] and chronic liver disease [CLD]) (5).
Despite this warning, recent estimates suggest that 20% to 30% of persons receiving metformin have historical contraindications or precautions regarding its use (6, 7). These findings reflect that many prescribers believe the FDA boxed warning is too restrictive (8, 9) . Literature reviews indicate no clear association between metformin use and lactic acidosis (10) and suggest that the drug is safe for patients with moderate CKD or CHF (11, 12) . In 2006, the FDA removed CHF as a contraindication to metformin use, although acute or unstable CHF remains a precaution (13, 14) . In April 2016, the FDA revised its warning regarding metformin use in patients with CKD, switching from a serum creatinine-based definition of renal impairment to moreinclusive criteria based on estimated glomerular filtration rate (eGFR) (15). With this change, an estimated 1 million additional patients with moderate CKD (eGFR, 30 to <60 mL/min/1.73 m 2 ) became eligible to receive metformin, although severe CKD (eGFR, <30 mL/min/ 1.73 m 2 ) remains a contraindication (16). In the wake of these changes, metformin use will continue to increase in populations with historical contraindications and precautions. Prescribers therefore must fully understand the consequences of metformin use in these groups. To promote informed prescribing, we systematically reviewed the literature regarding the benefits and harms of metformin use (beyond lactic acidosis) among patients with common chronic diseases historically identified by the FDA's boxed warning as contraindications or precautions: moderate to severe CKD, CHF, and CLD with impaired hepatic function.
METHODS

Study Design
This work was part of a Veterans Health Administration (VHA)-funded report. Additional details are available online (www.hsrd.research.va.gov/publications /esp). The present analysis focuses on the following question: For patients with type 2 diabetes and a historical contraindication or precaution regarding metformin use, what are the benefits and harms (beyond lactic acidosis) of metformin treatment?
This review followed a published protocol (PROSPERO: CRD42016027708), and each step was pilot-tested to train and calibrate investigators.
Data Sources and Study Selection
In consultation with an expert medical librarian, we searched PubMed, the Cochrane Central Register of Controlled Trials, EMBASE, and the International Pharmaceutical Abstracts in November 2015; we subsequently updated our PubMed search through September 2016. We also searched ClinicalTrials.gov for relevant completed and ongoing studies. Appendix Table 1 (available at Annals.org) presents our search strategies. We also screened reference lists of published reviews and queried Bristol-Myers Squibb, the manufacturer of the branded metformin formulation, for other relevant studies.
Our prespecified inclusion and exclusion criteria are listed in Appendix Table 2 (available at Annals.org). We included English-language clinical trials and observational cohort studies that examined adults with type 2 diabetes and a metformin contraindication or precaution of interest (moderate to severe CKD [eGFR, <60 mL/min/1.73 m 2 ], CHF, or CLD with hepatic impairment); compared antihyperglycemic regimens that included metformin with those that did not; and reported all-cause mortality, major adverse cardiovascular events (MACEs), glycemic control, lipid control, hypoglycemia, weight gain, or vitamin B 12 deficiency. Our VHA stakeholders and technical expert panel provided guidance on outcome selection.
Data Extraction and Quality Assessment of Individual Studies
Two investigators screened all citations for eligibility, and citations considered relevant by either individual advanced to full-text review. Two investigators reviewed all full-text articles and resolved disagreements through discussion or adjudication by a third investigator. Before excluding any potentially eligible study whose primary analysis did not explicitly address a population with a metformin contraindication or precaution, we examined the full text for relevant subgroup analyses.
Two investigators independently assessed study quality, and disagreements were resolved by consensus or through arbitration by a third investigator. Using published quality criteria, we developed a customized risk-of-bias (ROB) assessment tool designed to address selection, performance, attrition, detection, and reporting biases (Appendix Figure 1 , available at Annals.org) (17). We assigned each study an ROB score (low, moderate, or high).
Data Abstraction
For each included study, an investigator abstracted data by using a customized DistillerSR database (Evidence Partners); a second investigator independently reviewed these data for accuracy. Relevant data included demographics, study setting, contraindication or precaution definitions, metformin dosage, other antihyperglycemic agents, comparators, and outcomes. We treated multiple publications from a single study as a single data point, prioritizing the longestterm and most complete results. If critical data were missing or unclear in a published report, we contacted the manuscript authors.
Data Synthesis
We developed summary tables to characterize all included studies for each metformin contraindication or precaution of interest. Of note, 2 studies (18, 19) separately compared distinct groups of metformin users-those receiving metformin monotherapy and those receiving metformin-sulfonylurea combination therapy-with patients receiving sulfonylurea monotherapy. In each case, we derived a pooled, weighted hazard ratio (HR) for all metformin users, incorporating an approximation of the correlation resulting from the shared sulfonylurea monotherapy reference group (Appendix, available at Annals.org). For another study (20), we estimated the HR and variance from the reported frequencies and the odds ratio (OR) by using an established approach (21, 22) (Appendix).
If 3 or more studies were conceptually similar in terms of design, population, intervention, and outcomes, we performed quantitative synthesis by using a random-effects model to generate summary HRs. For analyses with fewer than 20 studies, we used the KnappHartung approach to adjust the SEs of the estimated coefficients (23, 24) . If appropriate, we conducted sensitivity analyses by omitting subgroups with more severe contraindications or precautions (such as an eGFR <30 mL/min/1.73 m 2 ), studies with shorter follow-up (<2 years), and studies not using propensity-score adjustment. We evaluated statistical heterogeneity by using Cochran Q and I 2 statistics; for analyses including 10 or more studies, we assessed publication bias by using funnel plots and Begg and Egger tests (25, 26) . For cases with too few studies to warrant meta-analysis, we performed qualitative synthesis.
We conducted all quantitative analyses by using R (version 3.1.2) (The R Foundation), including the "metafor" package (version 1.9-7), for meta-analysis.
Strength of Evidence
We used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to evaluate the overall strength of evidence (SOE) for outcomes with sufficient data. Using the domains of ROB, directness, and consistency or precision of treatment effects, an investigator (J.W.W.) rated the SOE as high, moderate, low, or insufficient. We consid-ered the effect of residual confounders, magnitude of effect, and publication bias (27, 28) .
Role of the Funding Source
This review was funded by the U.S. Department of Veterans Affairs. The funding source had no role in the study design, data collection, analysis, preparation of the manuscript, or decision to submit the manuscript for publication.
RESULTS
From 4910 screened citations, we reviewed 532 full-text articles and identified 17 eligible studies (Figure 1 ). All were observational and addressed populations with moderate to severe CKD (n = 5), CHF (n = 11), or CLD with hepatic impairment (n = 3); 3 studies addressed both CKD and CHF. Appendix Table 3 (available at Annals.org) provides details on the included studies. Of note, we identified no ongoing studies in ClinicalTrials.gov that met our inclusion criteria.
CKD
Six observational studies-4 retrospective cohort studies (29 -32), 1 prospective cohort study (33), and 1 nested case-control investigation derived from a cohort study (34)-evaluated metformin's effect on relevant outcomes in patients with type 2 diabetes and moderate to severe CKD. Sample sizes ranged from 1246 to 11 481 patients with moderate to severe CKD, and mean or median age ranged from 65 to 76 years. Definitions of CKD varied among studies, with 4 reporting eGFR-based (29, 30, 33, 34) and 2 serum creatinine-based definitions (31, 32) . Only 1 study reported a median daily metformin dose (1100 to 1900 mg in various subgroups) (30). All studies adjusted for several baseline population differences between metformin users and nonusers; 3 used propensity scores (29, 30, 33) . Follow-up ranged from 1 to 3.9 years. Two studies had low ROB (29, 32) and 4 moderate ROB (30, 31, 33, 34) .
All-Cause Mortality
Five studies (n = 33 442) examined all-cause mortality, defined by medical records or administrative data in 4 studies (29 -32) and prospective assessment in 1 study (33) . Rather than comparing metformin with specific alternatives, all studies compared diabetes treatment regimens that included metformin with those that did not. On meta-analysis, the relative chance of dying during follow-up was 22% lower for patients receiving metformin than for those not receiving it (HR, 0.78 [95% CI, 0.63 to 0.96] ; Q = 29.7 [P < 0.001]; I 2 = 79.8%) (Figure 2 ). Sensitivity analyses examining 3 studies (29, 30, 32) with follow-up of 2 years or longer and 3 that used propensity-score adjustment (29, 30, 33) yielded HR point estimates and statistical heterogeneity similar to those of our main analysis.
Two studies reported mortality by CKD severity subcategory and suggested that patients with an eGFR of 30 to less than 45 mL/min/1.73 m 2 received less benefit from metformin than patients with an eGFR of 45 to less than 60 mL/min/1.73 m 2 ( Figure 2 ) (30, 33). A sensitivity analysis excluding 573 patients with an eGFR less than 30 mL/min/1.73 m 2 -a level of kidney impairment at which metformin remains contraindicatedproduced findings similar to those of the main metaanalysis (33).
MACEs
Two studies (n = 14 408) examined MACEs with diabetes treatment regimens including metformin versus those without it (30, 31). One study used administrative data to identify MACE-related diagnoses (including myocardial infarction, angina, stroke, and procedures) and found no difference in outcomes with metformin use between patients with an eGFR of 45 to less than 60 mL/min/ 
Hypoglycemia
One study (n = 1644 patients with an eGFR <60 mL/min/1.73 m 2 ) used diagnosis codes to examine hypoglycemia with use of metformin, glyburide, or insulin monotherapy (34). With metformin as the reference group, both glyburide (adjusted OR, 6.0 [CI, 3.8 to 9.5]) 
CHF
Eleven observational studies-8 retrospective cohort studies (18, 19, 29, 31, 35, 36 -38) , 2 prospective cohort studies (33, 39) , and 1 nested case-control investigation derived from a cohort study (20)-evaluated metformin's effect on relevant outcomes in patients with type 2 diabetes and CHF. The entire population had CHF in 9 studies (18 -20, 29, 31, 35, 36, 37) , and we examined CHF subgroups in the remaining 2 (33, 38). Sample sizes ranged from 346 to 13 930 patients with CHF, and mean or median age ranged from 55 to 77 years. Definitions of CHF varied widely, with most studies using diagnosis codes. Severity of CHF was reported in various ways: 4 studies reported left ventricular ejection fraction (LVEF) (29, 31, 37, 39) , 2 reported New York Heart Association class (both of which also reported LVEF) (37, 39), 2 reported other clinical criteria (18, 36), and 5 did not report CHF severity (19, 20, 33, 35, 38) . No studies reported median metformin dosage. All studies adjusted for several baseline population differences between metformin users and nonusers; 5 used propensity scores (19, 20, 29, 33, 39) . Follow-up ranged from 1 to 4.7 years. Two studies had low ROB (29, 39); the others had moderate ROB.
All-Cause Mortality
Eleven studies (n = 35 410) examined all-cause mortality, defined by using medical records or administrative data in 9 studies (18, 20, 29, 31, (35) (36) (37) (38) (39) and prospective assessment in 1 study (33); all-cause mortality was not defined in 1 study (19) . Nine studies compared diabetes treatment regimens that included metformin with those that did not, whereas 2 compared metformin with sulfonylurea monotherapy (18, 19) . On meta-analysis, the relative chance of dying during follow-up was 22% lower for patients receiving metformin than for those not receiving it (HR, 0.78 [CI, 0.71 to 0.87]; Q = 26.6 [P = 0.003]; I 2 = 62.3%) (Figure 3 ). Sensitivity analyses examining 7 studies (18, 19, 29, 35, (37) (38) (39) with a follow-up of 2 years or longer and 5 studies (19, 20, 29, 33, 39 ) that used propensity-score adjustment yielded HR point estimates and statistical heterogeneity similar to those of our main analysis. Inspection of a funnel plot showed no clear evidence of publication bias (Appendix Figure 2 , Annals.org), nor did Begg (P = 0.16) and Egger (P = 0.09) tests.
Two studies examined mortality by CHF severity. One study reported mortality by LVEF category and found no difference with metformin use versus nonuse within subgroups with moderate (LVEF, 30% to 39%; HR, 0.87 [CI, 0.67 Studies are listed according to increasing CKD severity. Eckströ m and colleagues (30) and Roussel and colleagues (33) stratified their respective populations by eGFR; these eGFR categories are presented separately for these studies. Summary data above the horizontal dashed line reflect a sensitivity analysis excluding 573 patients with an eGFR <30 mL/min/1.73 m 2 . CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; HR = hazard ratio; M = men; ROB = risk of bias; SCr = serum creatinine; W = women. * 1.5 mg/dL. † 1.4 mg/dL. ‡ Numbers do not total 100% because of rounding.
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MACEs
Six studies used medical records or administrative data to examine MACEs, with 4 (n = 26 510) evaluating CHF readmission (20, 29, 31, 39 ) and 3 (n = 6468) investigating cardiovascular mortality (18, 19, 39) . In all, 4 studies compared diabetes treatment regimens that included metformin with those that did not, whereas 2 compared metformin with sulfonylurea monotherapy (18, 19) . We performed separate meta-analyses for each MACE outcome. On meta-analysis, the relative chance of readmission for CHF during follow-up was 13% lower for patients receiving metformin than for those not receiving it (HR, 0.87 [CI, 0.78 
CLD
Three observational cohort studies-2 retrospective (40, 41) and 1 prospective (42)-evaluated the effect of metformin on relevant outcomes in patients with type 2 diabetes and CLD with cirrhosis defined by histology. We therefore considered all patients as having "impaired hepatic function," as specified by the FDA boxed warning (5). Individual sample sizes ranged from 82 to 250 patients, and mean or median age ranged Studies are listed chronologically. CHF = congestive heart failure; HR = hazard ratio; ROB = risk of bias. Studies are listed chronologically. CHF = congestive heart failure; HR = hazard ratio; ROB = risk of bias. * Numbers do not total 100% because of rounding.
from 60 to 61 years. No studies reported the median metformin dosage. Follow-up ranged from 4.5 to 5.7 years. One study had low (41) and 1 moderate ROB (40). The third study was well-designed overall but had high ROB regarding all-cause mortality (42); the primary outcome was liver-specific mortality, and only unadjusted all-cause mortality rates could be derived.
All-Cause Mortality
Three studies (n = 432) examined all-cause mortality, defined by using medical records or administrative data in 2 studies (40, 41) and prospective assessment in 1 study (42) . Each study compared diabetes treatment regimens that included metformin with those that did not. All studies adjusted for baseline population differences between metformin users and nonusers for their primary analyses; however, for 2 studies we could abstract only unadjusted event rates for all-cause mortality (40, 42) . Because of these differences in outcome reporting, we did not attempt meta-analysis.
The low-ROB study found significantly longer survival associated with metformin use (n = 250; HR, 0.43 [CI, 0.24 
Other Outcomes
We identified no studies evaluating metformin's effects on glycemic control, lipid control, weight gain, or B 12 deficiency in adults with diabetes and contraindications or precautions of interest. We found no studies evaluating hypoglycemia in adults with diabetes and CHF or CLD, or MACEs in adults with diabetes and CLD.
Study Quality
Most studies had moderate or low ROB (Appendix Table 4 , available at Annals.org). Common quality concerns included incomplete accounting for baseline population differences and confounding by indication, although some studies did use propensity scores; limited assessment of metformin use throughout the study period (for example, assessment at baseline without accounting for subsequent metformin discontinuation or initiation), although some studies did analyze metformin exposure status in "intervals" to account for this concern; incomplete assessment and description of attrition; and unblinded outcome assessment.
SOE
The Table summarizes the overall SOE regarding metformin's effect on all-cause mortality and MACEs among patients with moderate to severe CKD or CHF. We assessed SOE only for outcomes for which the number of studies warranted meta-analysis. For allcause mortality, the SOE for reduced mortality was low among metformin users with moderate to severe CKD or CHF. Likewise, the SOE supporting reduced CHF readmission was low among metformin users with CHF; the evidence for reduced cardiovascular mortality in this group was insufficient.
DISCUSSION
Following the recent FDA labeling changes, metformin use in populations with historical contraindications or precautions will continue to increase. This systematic review sought to inform prescribing by examining clinical outcomes associated with metformin use among adults with type 2 diabetes and comorbid moderate to severe CKD, CHF, or CLD with impaired hepatic function. On the basis of available observational evidence, we found that metformin therapy seems to be associated with reduced all-cause mortality among patients with moderate CKD, CHF, or CLD with impaired hepatic function; fewer CHF readmis- Studies are listed chronologically. CHF = congestive heart failure; HR = hazard ratio; ROB = risk of bias.
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Metformin Use in Populations With CKD, CHF, or CLD sions among those with moderate CKD or CHF; and a lower hypoglycemia rate among those with moderate CKD.
As the consensus first-line therapy in type 2 diabetes, metformin is the most widely prescribed diabetes drug in the world (43). Beyond its glycemic effects, metformin is appealing because it is weight-neutral and safe, and may be associated with improved long-term outcomes in general diabetes populations (1-3). Although data were limited, we found no evidence to suggest that metformin's benefits do not extend to patients with moderate CKD, CHF, or CLD with impaired hepatic function. Together with reports regarding the safety of metformin with respect to lactic acidosis (10, 11), our findings support the FDA's recent actions.
This analysis adds to existing knowledge about metformin's effects on mortality outcomes. On the basis of a meta-analysis of 35 randomized, controlled trials (RCTs) reported through October 2009, Lamanna and colleagues (2) concluded that metformin monotherapy likely is associated with improved survival. In a subsequent analysis of 6 RCTs and 8 observational studies reported between April 2009 and April 2015, Bolen and colleagues (3) found lower cardiovascular mortality with metformin versus sulfonylurea therapy (risk difference, 0.1% to 2.9% in RCTs). In contrast, Palmer and colleagues (44) conducted a network metaanalysis of 25 comparative monotherapy studies reported through March 2016 and found that cardiovascular mortality did not differ between diabetes medication classes, including metformin; of note, this analysis included only 67 total cardiovascular deaths. Our review differs from these analyses in that we focused on diabetes populations with historical metformin contraindications or precautions. Consequently, we analyzed observational studies with longer followups, which in some ways are better suited for examining outcomes that require long-term observation (such as mortality). Our findings are consistent with those of Eurich and colleagues (12), who found that metformin use is associated with reduced mortality in CHF; our analysis included 3 additional studies (n = 6514) (20, 38, 39) and excluded another study without an active comparator (45).
Beyond providing information for prescribers, this review may help inform revision of clinical guidelines. The 2016 American Diabetes Association guidelines note that "accumulating observational data suggest that metformin may be safely continued down to glomerular filtration rate (GFR) of 45 mL/min/1.73 m 2 or even 30 mL/min/1.73 m 2 " (1). Given the apparent mortality reduction associated with metformin use in diabetes patients with moderate CKD and other relevant comorbidities, this review may support strengthening this endorsement.
Although we used a rigorous, protocol-driven approach, our analysis has limitations. First, to assure relevance for our VHA stakeholders, we limited our search to studies from Organization for Economic Cooperation and Development (OECD) countries (46), which may have excluded potentially relevant articles from non-OECD nations. Second, although we examined many outcomes, we did not examine all outcomes of potential interest. Because our objective was informing metformin prescribing, we focused on the most clinically relevant outcomes for our stakeholders.
The observational evidence base warrants additional caution when interpreting our findings. First, such registries as ClinicalTrials.gov do not include observational studies, which limited our ability to assess for publication bias. Second, although most studies adjusted for baseline differences between metformin users and nonusers (sometimes including propensity scores), confounding by indication remains a potential source of unmeasured population differences. For example, many studies did not report outcomes based on contraindication or precaution severity, so unaccountedfor between-group differences in disease severity may have influenced our findings. Of note, sensitivity analyses examining studies using propensity-score adjustment yielded HR point estimates similar to those of our main analyses, but substantially reduced statistical het- (48); however, sensitivity analyses examining studies with follow-ups of 2 years or longer yielded results similar to those of our main analysis. All these limitations may have contributed to the statistical heterogeneity observed in our quantitative syntheses. However, because most meta-analyzed studies showed metformin to be associated with improved outcomes of interest, this heterogeneity seems to be related to variance in the precise magnitude of an overall effect consistently favoring metformin. As such, the observed heterogeneity does not invalidate our findings.
To date, most metformin trials have excluded patients with moderate to severe CKD, CHF, or CLD. The primary evidence gap regarding metformin use in patients with historical contraindications or precautions is therefore the absence of RCTs. Various factors reduce the feasibility of future metformin RCTs in these populations; metformin is a generic medication widely viewed as a first-line treatment, and the length of time required to assess mortality and MACEs may be prohibitive. Even without RCTs, new observational studies might ensure that deleterious outcomes do not become more apparent as metformin prescribing increases in populations with historical contraindications or precautions. Of note, we identified no such ongoing studies in ClinicalTrials.gov that met our inclusion criteria.
The effect of contraindication or precaution severity on the apparently beneficial effects of metformin remains unclear. For example, although our primary CKD meta-analysis included patients with a range of eGFR values less than 60 mL/min/1.73 m 2 , additional studies focusing specifically on cohorts with eGFRs of 30 to 45 mL/min/1.73 m 2 , or even less than 30 mL/min/1.73 m 2 , would further inform metformin prescribing and guideline refinement. Data regarding precaution severity in CHF and CLD are sparse, and observational research might address these gaps.
Building on the issue of severity, the possibility of tailoring metformin prescribing based on the severity of historical contraindications or precautions would benefit from further research. Canadian prescribing guidelines have long recommended metformin dosage reduction based on eGFR (49), and U.S. thought leaders have suggested a maximum metformin dosage of 2550 mg/d for patients with an eGFR of 60 mL/min/ 1.73 m 2 or greater, 2000 mg/d for those with an eGFR of 45 to less than 60 mL/min/1.73 m 2 , and 1000 mg/d for those with an eGFR of 30 to less than 45 mL/min/ 1.73 m 2 (11). Given that metformin is excreted unchanged in the urine (50), dosage adjustment has a clear rationale; however, no trial data and only limited observational data exist to support this approach.
Finally, because diabetes medication classes have varying effects on cardiovascular outcomes (51, 52), additional research comparing metformin with specific alternative agents in populations with historical contraindications or precautions would help refine prescribing guidelines for these groups.
On the basis of limited evidence, metformin is associated with reduced all-cause mortality in patients with moderate CKD, CHF, or CLD with impaired hepatic function. Further, metformin may be associated with reduced CHF readmissions in patients with moderate CKD or CHF and lower hypoglycemia incidence in patients with moderate CKD. Available data provide no evidence that the risks associated with metformin exceed those of other antihyperglycemic medications in these populations. Our findings support the recent FDA labeling changes, point toward areas for future research, and may help inform clinical practice and revision of clinical guidelines. 
APPENDIX: TECHNICAL DETAILS Pooling Hazard Ratios
Example: all-cause mortality using Andersson and colleagues (18) (Appendix Table 5 ).
The HR for comparing pooled metformin monotherapy and metformin-plus-sulfonylurea groups (numerator) with the reference (control) group of sulfonylurea monotherapy is a weighted estimate:
ln 
Approximation of HR From Reported
Adjusted OR Example: all-cause mortality using Weir and colleagues (20) (Appendix Table 6 ).
First, compute (U denotes the upper and L the lower limit of the 95% CI for OR) Based on the aforementioned expression for OR, the proportion p 1 may be expressed as a function of p 0 and OR as follows:
Substituting into the expression for Var and solving the resulting nonlinear equation numerically, one obtains p 0 . For the aforementioned data (OR, L, U, n 0 , n 1 ), 2 solutions are possible: 0.0587016 and 0.9741263. Based on the reported mortality rates in patients receiving sulfonylurea monotherapy, we chose p 0 = 0.0587016. Thus, Kosinski derived the aforementioned approach independently in 2015 (not published). However, a similar approach for estimating p 0 and p 1 was implemented with the "orsk" library in the R package (21), extending a published approach to converting OR to relative risk that relies on the availability of p 0 (22). The orsk package uses a constrained, nonlinear optimization formulation, which is solved by a grid search or a nonlinear optimization algorithm, and provides a selection of possible p 0 (ctr_risk) and p 1 (trt_risk) With p 0 and p 1 now available (we used the approach by Kosinski), the HR is estimated by assuming exponential distribution for time to death, as suggested by Hasselblad (not published): 
As a final step, one computes a 95% CI for the true HR as follows: 5 "lactic acidosis":ab,ti OR hyperlactatemia:ab,ti OR hyperlactataemia:ab,ti OR CKD:ab,ti OR CRD:ab,ti OR "chronic kidney":ab,ti OR "chronic renal":ab,ti OR "heart failure":ab,ti OR CHF:ab,ti OR "chronic liver disease":ab,ti OR "liver insufficiency":ab,ti OR "hepatic insufficiency":ab,ti OR "liver cirrhosis":ab,ti OR "diabetic nephropathies":ab,ti OR "diabetic nephropathy":ab,ti OR aged:ab,ti OR elderly:ab,ti OR older:ab,ti OR geriatric:ab,ti 
Inclusion/Exclusion Criteria
Population Adults (≥18 years) with T2D (using criteria valid at the time of the study) and 1 of the following contraindications/precautions to metformin use: CKD, CHF, CLD, or older age as defined by authors of the primary study. Exclusions: Mixed samples in which <80% have ≥1 of the specified contraindications/precautions, and results are not reported by subgroup. Studies in which <80% of the sample has T2D. The rationale is that relatively homogeneous samples of the population of interest are required to evaluate metformin effects. Samples with prediabetes or metabolic syndrome, gestational diabetes mellitus, acute kidney injury in the absence of CKD, end-stage renal disease on hemodialysis, and contrast exposure (e.g., contrast-enhanced imaging procedures). CKD may be defined as an elevated creatinine or eGFR <60 mL/min/1.73 m 2 ; microalbuminuria alone is not considered CKD for the purposes of this review.
Interventions
Metformin use alone or in combination with other glucose-lowering treatment.
Exclusion: Phenformin Comparators
Nonmetformin oral or injectable hypoglycemic medication(s) in the presence of a traditional contraindication or precaution to metformin use Exclusion: Studies that did not allow evaluation of the effect of metformin (e.g., studies that compared metformin plus a hypoglycemic medication to metformin plus a different hypoglycemic medication) Outcomes Benefits evaluated include glycemic control (i.e., hemoglobin A 1c ), lipid control, MACEs (e.g., MI, CHF hospitalization), cardiovascular-related mortality, and all-cause mortality; harms included hypoglycemia and weight gain. Exclusion: Studies reporting outcomes other than a specified outcome of interest Timing
Studies reporting outcomes at ≥28 days (approximately 1 month) after initiation of metformin or switching to another medication Setting Outpatient or population based Study design RCTs, nonrandomized clinical trials, and comparative prospective and retrospective cohort studies (including nested case-control studies derived from cohorts) Publication type
Full publications in English-language, peer-reviewed journals Exclusions: Meeting abstracts, letters, editorials, and dissertations Limits Studies were limited to the 34 countries that are part of the OECD (46). The rationale is to limit to countries where T2D is more prevalent and the general medical care is similar to that in United States. We searched from 1994, the year that metformin was approved by the FDA, through the present. CHF = congestive heart failure; CKD = chronic kidney disease; CLD = chronic liver disease; eGFR = estimated glomerular filtration rate; FDA = U.S. Food and Drug Administration; MACEs = major adverse cardiovascular events; MI = myocardial infarction; OECD = Organization for Economic Cooperation and Development; RCT = randomized, controlled trial; T2D = type 2 diabetes. 
